Emerging drugs for alopecia areata: JAK inhibitors

References

• Messenger AG, McKillop J, Farrant P, et al. British association of dermatologists’ guidelines for the management of alopecia areata. Br J Dermatol. 2012;166(5):916–926.
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24.
   PubMed Web of Science ®Google Scholar
• Tosti A, Iorizzo M, Bellavista S. Alopecia areata: a long-term follow up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438–441.
   PubMed Web of Science ®Google Scholar
• Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):231–246.
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Pazzaglia M, et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49(1):96–98.
   PubMed Web of Science ®Google Scholar
• Tosti A, Iorizzo M, Botta GL, et al. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006;20(10):1243–1247.
   PubMed Web of Science ®Google Scholar
• Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol. 2009;8(10):909–912.
   PubMed Web of Science ®Google Scholar
• Chu TW, Al Jasser M, Alharbi A, et al. Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study. J Am Acad Dermatol. 2015;73(2):338–340.
   PubMed Web of Science ®Google Scholar
• Friedli A, Labarthe MP, Engelhardt E, et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol. 1998;39(4Pt1):597–602.
   PubMedGoogle Scholar
• Smith A, Trueb RM, Theiler M, et al. High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata. Pediatr Dermatol. 2015;32(4):481–487.
   PubMed Web of Science ®Google Scholar
• Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol. 1996;35(2):133–136.
   PubMed Web of Science ®Google Scholar
• Vano-Galvan S, Hermosa-Gelbard Á, Sánchez-Neila N, et al. Pulse corticosteroid, therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. J Am Acad Dermatol. 2016;74(5):1005–1007.
   PubMed Web of Science ®Google Scholar
• Rokhsar CK, Shupack JL, Vafai JJ, et al. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998;39(5Pt1):751–761.
   PubMed Web of Science ®Google Scholar
• Jang YH, Jung HJ, Moon SY, et al. Systematic review and quality analysis of studies on the efficacy of topical DPCP treatment for alopecia areata. J Am Acad Dermatol. 2017;77(1):170–172.
   PubMed Web of Science ®Google Scholar
• Singh G, Lavanya M. Topical immunotherapy in alopecia areata. Int J Trichology. 2010;2(1):36–39.
   PubMedGoogle Scholar
• Trueeb R, Gavazzoni Dias MF. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2018;54(1):68-87.
   Web of Science ®Google Scholar
• Gilhar A, Schrum AG, Etzioni A, et al. Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Res. 2016;15(7):726–735.
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic lymphocytes and is reversed by JAK inhibitors. Nat Med. 2014;20(9):1043–1049.
   PubMed Web of Science ®Google Scholar
• Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, Ferdinand JR, et al. Mechanism of JAK/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21–27.
   PubMed Web of Science ®Google Scholar
• Divito SJ, Kupper TS. Inhibiting janus kinases to treat alopecia areata. Nat Med. 2014;20(9):989–990.
   PubMed Web of Science ®Google Scholar
• Alves De Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment in inflammatory skin diseases. PLOSone. 2016;11(10):e0164080.
   PubMed Web of Science ®Google Scholar
• Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Cerise J, Chen JC, et al. An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata (abstract). J Invest Dermatol. 2016;136(5):S49.
   Web of Science ®Google Scholar
• Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–28.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29–32.
   PubMed Web of Science ®Google Scholar
• Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–355.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. 2015;152(4):490–491.
   Web of Science ®Google Scholar
• Bayart CB, DeNiro KL, Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–170.
   PubMed Web of Science ®Google Scholar
• Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol 2018;78(2):403-404.
   Web of Science ®Google Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744.
   PubMed Web of Science ®Google Scholar
• Shreberk-Hassidim R, Ramot Y, Zlotogorsky A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745–753.
   PubMed Web of Science ®Google Scholar
• Di Lernia V. Targeting the IFNγ-CXCL10 pathway in lichen planus. Medical Hypotheses. 2016;92:60–61.
   PubMed Web of Science ®Google Scholar
• Farmer LJ, Ledeboer MW, Hoock T, et al. Discovery of VX-509 (Decernotinib): a potent and selective janus kinase 3 inhibitor for the treatment of autoimmune diseases. J Med Chem. 2015;58(18):7195–7196.
   PubMed Web of Science ®Google Scholar